190 related articles for article (PubMed ID: 31616059)
1. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Fuentes P; Roldán J; González-Farré B; Rosich L; Silkenstedt E; García-León MJ; Lee-Vergés E; Giménez N; Giró A; Aymerich M; Villamor N; Delgado J; López-Guillermo A; Puente XS; Campo E; Toribio ML; Colomer D
Oncogene; 2020 Feb; 39(6):1185-1197. PubMed ID: 31616059
[TBL] [Abstract][Full Text] [Related]
2. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
3. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
[TBL] [Abstract][Full Text] [Related]
4. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.
Pozzo F; Bittolo T; Vendramini E; Bomben R; Bulian P; Rossi FM; Zucchetto A; Tissino E; Degan M; D'Arena G; Di Raimondo F; Zaja F; Pozzato G; Rossi D; Gaidano G; Del Poeta G; Gattei V; Dal Bo M
Leukemia; 2017 Nov; 31(11):2407-2415. PubMed ID: 28321119
[TBL] [Abstract][Full Text] [Related]
5. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
6. A novel peptide inhibitor of Dll4-Notch1 signalling and its pro-angiogenic functions.
Zhu G; Lin Y; Ge T; Singh S; Liu H; Fan L; Wang S; Rhen J; Jiang D; Lyu Y; Yin Y; Li X; Benoit DSW; Li W; Xu Y; Pang J
Br J Pharmacol; 2022 Apr; 179(8):1716-1731. PubMed ID: 34796471
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
8. Dll4/Notch1 signalling pathway is required in collective invasion of salivary adenoid cystic carcinoma.
Wang K; Fan HY; Pang X; Zhang M; Yu XH; Wu JS; Chen BJ; Jiang J; Liang XH; Tang YL
Oncol Rep; 2021 Mar; 45(3):1011-1022. PubMed ID: 33469672
[TBL] [Abstract][Full Text] [Related]
9. Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway.
Zhang Y; Zhang Y; Wang J; Gu H
Biomed Res Int; 2020; 2020():5391058. PubMed ID: 33145353
[TBL] [Abstract][Full Text] [Related]
10. Neuritin promotes angiogenesis through inhibition of DLL4/Notch signaling pathway.
Yang L; Wang X; Sun J; Liu C; Li G; Zhu J; Huang J
Acta Biochim Biophys Sin (Shanghai); 2021 May; 53(6):663-672. PubMed ID: 33787845
[TBL] [Abstract][Full Text] [Related]
11. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
12. Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1.
Pedrosa AR; Trindade A; Fernandes AC; Carvalho C; Gigante J; Tavares AT; Diéguez-Hurtado R; Yagita H; Adams RH; Duarte A
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1134-46. PubMed ID: 25767274
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of c-Myc-dependent heterogeneous nuclear ribonucleoprotein A1 promotes proliferation and inhibits apoptosis in NOTCH1-mutated chronic lymphocytic leukemia cells.
Zou Y; Tang H; Miao Y; Zhu H; Wang L; Fan L; Fu J; Xu W; Li J; Xia Y
Chin Med J (Engl); 2022 Apr; 135(8):920-929. PubMed ID: 35730371
[TBL] [Abstract][Full Text] [Related]
14. IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.
De Falco F; Del Papa B; Baldoni S; Sabatini R; Falzetti F; Di Ianni M; Martelli MP; Mezzasoma F; Pelullo M; Marconi P; Sportoletti P; Screpanti I; Rosati E
Cell Death Dis; 2018 Nov; 9(12):1160. PubMed ID: 30478302
[TBL] [Abstract][Full Text] [Related]
15. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.
Baldoni S; Del Papa B; Dorillo E; Aureli P; De Falco F; Rompietti C; Sorcini D; Varasano E; Cecchini D; Zei T; Di Tommaso A; Rosati E; Alexe G; Roti G; Stegmaier K; Di Ianni M; Falzetti F; Sportoletti P
Int J Cancer; 2018 Aug; 143(4):958-970. PubMed ID: 29508386
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
[TBL] [Abstract][Full Text] [Related]
17. G-Protein-Coupled Receptor-2-Interacting Protein-1 Controls Stalk Cell Fate by Inhibiting Delta-like 4-Notch1 Signaling.
Majumder S; Zhu G; Xu X; Senchanthisai S; Jiang D; Liu H; Xue C; Wang X; Coia H; Cui Z; Smolock EM; Libby RT; Berk BC; Pang J
Cell Rep; 2016 Dec; 17(10):2532-2541. PubMed ID: 27926858
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients.
Aref S; El-Agder M; Salama O; Abouzeid T; Sabry M
Asian Pac J Cancer Prev; 2020 May; 21(5):1295-1301. PubMed ID: 32458636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
